Company
AstraZeneca
AstraZeneca is a global pharmaceutical company that researches, develops, and commercializes prescription medicines across oncology, cardiovascular, respiratory, infectious disease, and rare disease therapy areas. The company focuses on transforming patient outcomes through innovative treatments and aims to deliver 20 new medicines by 2030. With $58.7 billion in annual revenue, AstraZeneca operates research centers globally and invests significantly in science and AI-driven drug development.
AstraZeneca is a publicly traded company operating in the pharmaceutical industry sector, based in the United Kingdom. It trades on the New York Stock Exchange under the ticker AZN. Leadership tracked by CEOInsider includes Pascal Soriot (CEO).
Leadership
Current
Recent developments
AI summary of recent coverageRecent coverage of AstraZeneca has focused on CEO Pascal Soriot's statements regarding the company's growth strategy, particularly highlighting the potential of its Summit drug candidate for next-generation cancer combinations following a $2 billion investment, and the opening of a new research and development center in Boston aimed at accelerating product development. The coverage also reflects Soriot's position that AstraZeneca can achieve growth objectives beyond 2030 without pursuing major acquisitions, alongside reports of the CEO's significant personal share purchases in the company.
Summarized from the headlines in the sidebar; see each source for the full story.